Canada: The Supreme Court Of Canada VIAGRA Case: 5 Messages Technology Businesses Should Receive

Last Updated: November 20 2012
Article by Dominique T. Hussey, L.E. Trent Horne and Edward (Ted) Yoo

In a unanimous decision, the Supreme Court of Canada has provided valuable guidance to patent agents and litigators as to how Canadian patents will be read and enforced (Teva Canada Limited v Pfizer Canada Inc, 2012 SCC 60).

The subject matter of the patent needs no introduction. Sildenafil is the active ingredient in VIAGRA, one of the world's best known pharmaceutical products. There is no mystery or uncertainty as to the reason VIAGRA is prescribed.

Pfizer's patent, however, was not as clear as the reputation its product enjoyed. The Pfizer patent described a class of compounds useful for the treatment of erectile dysfunction. The patent's description did not specifically identify sildenafil as an effective medication, even though Pfizer's tests conducted before the priority date showed that only sildenafil was effective for this purpose.

Pfizer's patent included a number of "cascading" claims, which defined the subject matter of the patent monopoly. Claim 1 set out a general formula which could produce 260 quintillion possible compounds used to treat erectile dysfunction. Successive claims narrowed the range of compounds monopolized; claims 6 and 7 related to a single compound each. Claim 7 related to sildenafil. Throughout the proceedings, Pfizer was unable to explain why its patent was directed to a number of compounds and why, although Pfizer knew that claim 7 claimed the only compound shown to be effective, the patent did not identify it as such or indicate that the remaining compounds had not been shown to be effective.

Message 1: Canadian Patent Law Drives a Hard Bargain

The main issue on the appeal was whether Pfizer had disclosed its invention sufficiently in its patent. The Supreme Court reiterated that proper disclosure is at the heart of the patent bargain; it is what the public receives in exchange for suffering a monopoly.

The disclosure end of the bargain is codified in s. 27(3) of the Patent Act, which requires that the patent specification "correctly and fully describe the invention and its operation or use as contemplated by the inventor". This, according to the Supreme Court, requires the patent to disclose the nature of the invention.

To determine the nature of the invention and whether disclosure is sufficient, the entire specification, including the claims, must be considered and must answer the familiar questions: What is the invention? How does it work?

But that does not end the inquiry. Once the monopoly period is over, a person skilled in the field of the invention must also be able to use the invention as successfully as the inventor could at the time of the patent application. To uphold the bargain, with respect to each invention in question, the description in the patent must enable the skilled person to produce the invention using only the instructions contained in the disclosure, and without even a minor research project.

If a disclosure falls short of these requirements: no deal. The invention will be deprived of patent protection as, the Supreme Court held, should be the fate of VIAGRA.

Message 2: E Pluribus, Unum: Out of Many Claims, One Invention

One of the more unexpected aspects of the decision was that the sufficiency of disclosure may - but will not necessarily - be considered on a claim-by-claim basis. In upholding the validity of the patent, the lower courts determined whether disclosure requirements had been met with respect to patent claims individually.

However, the Supreme Court held that this was the wrong approach. Rather, in assessing whether the disclosure requirements are met, the Court must consider the specification as a whole, including all of the claims; separate claims may not signify separate inventions. Section 58 of the Patent Act allows for a valid claim to survive despite one or more invalid claims, but this section applies only after the invalidity analysis, including whether disclosure requirements have been met.

The Supreme Court therefore rejected the proposition that where a valid claim exists, the consideration of disclosure requirements can be limited to that claim. Further, the proposition that each claim in a patent concerns a separate invention is contrary to the scheme of the Patent Act. As a result, the number of claims in a patent is not commensurate with the number of inventions. And whether a patent with several claims encompasses one or many inventions can be critical to its validity, as it was in this case.

Examining the specification as a whole, the Court found that sildenafil and the other compounds of the invention "were so linked as to form a single inventive concept in the patent at issue". Further, the specification did not contain any information to support the view that sildenafil for the treatment of erectile dysfunction is a separate invention from the use of any of the other quintillions of claimed compounds for that same purpose.

Accordingly, viewed as a whole, the patent at issue contained only one invention: the use of the compounds of a defined class that are effective in treating erectile dysfunction. However, because Pfizer had known that only one compound was in fact effective at the time of filing, the Court deemed this knowledge to define the true invention - and held that Pfizer had failed to disclose it adequately.

Message 3: Playing Hard to Get is a Risky Strategy

The Court unequivocally stated that there was no requirement to disclose in the patent the demonstration of the utility of the invention; but in this case, it was at the patentee's peril. The Supreme Court was influenced by, and showed disdain for, the apparent shell game Pfizer had played in failing to identify sildenafil as the effective compound among the quintillions in its patent.

The patent referred to a single "invention" throughout. It identified nine "especially preferred" compounds and specifically claimed just two. Pfizer had conducted tests that demonstrated that only sildenafil was effective in treating erectile dysfunction. This, according to the Court, should have been described in the patent to meet disclosure requirements.

The skilled person, having only the specification, could not put the invention into practice and needed to undertake a minor research project to determine what the true invention was.

The Supreme Court noted that Pfizer had chosen an opaque method of drafting its patent and failed to explain why it had elected to suppress information that sildenafil was the tested and useful compound. Gaming the system by enjoying exclusive monopoly rights while withholding disclosure was, "as as matter of policy and sound statutory interpretation", fatal to the patent.

Coyness, apparently, has no place in patent drafting. There is risk involved in less-than-full disclosure, particularly where the inventors have demonstrated utility. As a result, where a preferred embodiment of an invention has been tested and shown to work to the exclusion of other embodiments, disclosing this information in the patent appears to be critical. It is not enough to specifically claim the preferred embodiment and leave the skilled person to determine which one it is.

Message 4: There is Danger at the Bottom of the Patent Cascade

In a cascade of claims, Pfizer claimed a series of uses of compounds to treat erectile dysfunction starting with a claim that encompassed quintillions, and ending with two claims for individual compounds, one of which was the active ingredient in VIAGRA.

In practice, many patents are written with cascading claims that end with a series of individual claims. To the relief of patent agents everywhere, the Court did not throw out the practice of drafting cascading claims. The Court was careful to state that use of cascading claims "does not necessarily interfere in every case with the public's right to disclosure". The Court observed that the broad claims at the top of the cascade that include inoperative compounds are simply deemed invalid - presumably on the basis of inutility. The skilled reader knows that "when a patent contains cascading claims, the useful claim will usually be the one at the end concerning an individual compound".

Nevertheless, the Supreme Court held that where there were two individually claimed compounds, and it was known that one worked and the other did not, the true invention was obscured as the disclosure failed to state in clear terms what the invention was. The patent therefore failed to meet the disclosure requirement.

Patents with cascading claims are, therefore, susceptible to attack based on insufficient disclosure if the inventor's knowledge regarding utility or inutility of those individual claims is not disclosed. The Supreme Court has signaled heightened disclosure obligations for individually claimed inventions at the bottom of the cascade.

Message 5: Insufficiency is No Longer the Poor Step-Sibling of the Invalidity Trinity

Compared to anticipation, invalidity and inutility, insufficiency of disclosure has rarely been asserted successfully to invalidate patents or defend against infringement. The Supreme Court decision has, however, given this ground legitimacy and strength.

Although there is no express remedy for insufficient disclosure in the Patent Act, here, where the patent was found to encompass a single invention, failure of disclosure was said by the Supreme Court to have rendered the entire patent invalid. If there is no quid - proper disclosure - then there can be no quo - exclusive monopoly rights.

In the future, the insufficient disclosure ground is likely to be used (particularly against cascading patents) with greater frequency and success. This is especially so where utility has been demonstrated, but the demonstrated utility defines the invention in a manner not reflected in the patent description.

An earlier version of the article was published in SLAW.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Dominique T. Hussey
L.E. Trent Horne
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions